Sixty years after the first schizophrenia drug hit the market, researchers are still struggling to understand and treat the disorder. By Emily Elert.
A biochemical cascade
Dysregulation of glutamate may help explain why people with schizophrenia have too much dopamine in some parts of the brain and too little in others, giving rise to a broad spectrum of symptoms.
In 2012, researchers at the London School of Economics estimated that schizophrenia costs England more than £11.8 billion (US$19.7 billion) each year — nearly £76,00 for each person afflicted
The changing face of schizophrenia
15 years of drug development
The most widely used schizophrenia drugs, atypical antiphsychotics, are effective in treating positive symptoms. But researchers are finding new neural targets to address negative and cognitive symptoms.
For the past ten years, clinial trials of schizophrenia treatments have been on a downward trajectory, even though clinial trials in general have been rising.
About this article
The protective effects of Mogroside V and its metabolite 11-oxo-mogrol of intestinal microbiota against MK801-induced neuronal damages
Identification of potential serum biomarkers for breast cancer using a functional proteomics technology
Biomarker Research (2017)
Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology
Biomarker Research (2016)
Molecular Neurobiology (2016)